ClinicalTrials.Veeva

Menu

French Cohort Evaluating the effectiveneSs of Atrioventricular Synchrony by the micRa AV (AV-CESAR)

P

Paris Sudden Death Expertise Center

Status

Enrolling

Conditions

Atrioventricular Synchrony by the Micra AV

Treatments

Device: Patients implanted with Micra AV

Study type

Observational

Funder types

Other

Identifiers

NCT05953558
2023-A00023-42 Protocole

Details and patient eligibility

About

Transvenous cardiac pacemakers have pitfalls due to lead- and device pocket-related complications. Leadless pacemakers were developed and introduced into clinical practice to overcome the weaknesses of traditional transvenous pacemakers. The absence of atrial pacing has restricted their uses mainly for cases of paroxysmal atrioventricular block (AVB) or AVB with atrial fibrillation. The Micra AV contains an embedded accelerometer that senses the atrial contraction waveform, allowing the ventricle to be paced once the atrial contraction is complete. This atrioventricular synchronization is intended to extend the use of the device to cases of permanent complete AVB with normal sinus function. Two randomized clinicals trials have been proven it's efficacy. However, with AV-CESAR cohort, we aim to evaluate the real word effectiveness of Micra AV, in the first 1000 patients implanted by the device in France.

Enrollment

1,000 estimated patients

Sex

All

Ages

18 to 110 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • All patients who underwent Micra AV implantation

Exclusion criteria

  • Refusal of consent

Trial contacts and locations

1

Loading...

Central trial contact

Fawzi Kerkouri, MD; Eloi Marijon, MD,PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems